Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

Table 2 Demographic data of patients undergoing LVAD placement

	LVAD Implant (n = 57)	3 Months Post-LVAD (n = 17)	p-value*	6 Months Post-LVAD (n = 14)	p-value*	LVAD Explant (n = 23)	p-value*
Galectin-3 (ng/ml)	29.2 ± 14	23.7 ± 8	NS	21.7 ± 9	NS	40.4 ± 19	0.005
Age (yrs)	63 ± 10	65 ± 9	NS	60 ± 12	NS	63 ± 8	NS
Gender (% male)	91 %	100 %	NS	93 %	NS	87 %	NS
BMI (kg/m²)	28 ± 5	28 ± 4	NS	28 ± 5	NS	26 ± 4	NS
Etiology (%)
Ischemic	56 %	65 %	NS	64 %	NS	65 %	NS
Dilated	39 %	35 %		36 %		35 %
Hypertrophy	2 %	0 %		0 %		0 %
Unspecified	3 %	0 %		0 %		0 %
BNP (ng/mol)	1378 ± 1084	-	-	-	-	737 ± 470	0.01
LVAD Type (%)
Continuous	91 %	100 %	NS	82 %	NS	100 %	NS
Pulsatile	9 %	0 %		18 %		0 %
Comorbidities
Hypertension	54.4 %	64.7 %	NS	42.9 %	NS	47.8 %	NS
Previous MI^a	42.1 %	47.1 %	NS	35.7 %	NS	52.2 %	NS
Hyperlipidemia	45.6 %	52.9 %	NS	42.9 %	NS	47.8 %	NS
Diabetes	39.7 %	52.9 %	NS	21.4 %	NS	30.4 %	NS
Kidney Disease	38.1 %	64.7 %	NS	35.7 %	NS	43.5 %	NS
COPD^b	15.8 %	29.4 %	NS	7.1 %	NS	17.4 %	NS
Smoker	1.8 %	0 %	NS	0 %	NS	4.4 %	NS
Lab Values
WBC^c (x10³/μL)	9.0 ± 3	9.4 ± 4	NS	8.9 ± 4	NS	9.3 ± 4	NS
Hct^d (g/dL)	31 ± 10	32 ± 9	NS	35 ± 7	NS	30 ± 4	NS
Na^e (mEq/L)	136 ± 4	136 ± 4	NS	135 ± 4	NS	137 ± 4	NS
Crea^f (mg/dL)	1.5 ± 0.5	1.6 ± 0.4	NS	1.4 ± 0.5	NS	1.3 ± 0.6	NS
T-Bili^g (mg/dL)	1.6 ± 1.4	1.3 ± 0.4	NS	1.5 ± 1.7	NS	1.2 ± 0.9	NS
Albumin (g/dL)	3.6 ± 0.5	3.5 ± 0.5	NS	3.8 ± 0.4	NS	3.3 ± 0.5	0.02

*p value versus LVAD Implant
^aMI myocardial infarction, ^bCOPD chronic obstructive pulmonary disease, ^cWBC white blood count, ^dHct hematocrit, ^eNa sodium, ^fCrea creatinine, ^gT-Bili total bilirubin

ISSN: 1471-2261